What the Clinical Trials Actually Measure
Before comparing intermittent fasting protocols, it is worth being precise about what clinical trials in this area actually measure and what they do not. The outcomes most commonly studied are body weight and BMI, fasting glucose and insulin (and derived measures of insulin sensitivity like HOMA-IR), lipid panels, blood pressure, and inflammatory markers. A smaller subset of trials measures body composition — distinguishing fat mass from lean mass — which matters because weight loss that includes substantial lean mass loss has different health implications than fat-preferential weight loss. Adherence rates are increasingly reported as a primary outcome in protocol comparison studies, because a protocol that produces excellent metabolic results on paper but that most participants abandon within six weeks has limited practical value. With this framework in mind, the comparison between 16:8, 5:2, and OMAD looks somewhat different than the headline numbers might suggest.
The 16:8 Protocol
The 16:8 protocol — 16 hours of fasting with an 8-hour eating window daily — is the most extensively studied time-restricted eating approach and arguably the most accessible for daily implementation. Wilkinson et al. (2020), publishing in Cell Metabolism, studied a 10-hour eating window in 19 metabolic syndrome patients over 12 weeks. Without caloric restriction counseling or dietary modification beyond the eating window, participants showed significant improvements in body weight, blood pressure, atherogenic lipid levels, and fasting glucose. These results are notable because the metabolic improvements occurred with only eating window restriction, not explicit calorie counting. Harris et al. (2018), in a systematic review comparing IF protocols, found that 16:8 and similar daily time-restriction approaches produced consistent but modest weight loss — typically 1-5 percent of initial body weight over 8-12 week trials. The adherence data for 16:8 are generally favorable compared to more restrictive protocols: skipping breakfast or finishing eating in the early evening is a behavioral change most people can sustain over weeks and months.
The 5:2 Protocol
The 5:2 protocol involves five days of unrestricted eating and two non-consecutive days of substantial caloric restriction — typically 500-600 kcal on the restricted days. Harris et al. (2018) found that 5:2 produced metabolic outcomes broadly comparable to continuous caloric restriction and to daily time-restricted eating when compared directly in trials of similar duration. The mechanism differs from daily TRE: rather than restricting the eating window each day, 5:2 creates intermittent periods of significant energy deficit. The practical advantages are also different — many people find it more manageable to restrict substantially on two specific days per week than to maintain daily eating window discipline, especially given variable social and professional schedules. The disadvantages include the challenge of very-low-calorie intake on restricted days: hunger management, social eating conflicts, and fatigue are commonly reported. As with 16:8, the appropriate choice depends substantially on which behavioral pattern aligns with individual lifestyle, preference, and long-term adherence capacity.
OMAD: Limited Evidence Territory
One meal a day represents the most extreme form of daily time restriction, and it is important to be direct: the published evidence base for OMAD is substantially thinner than for either 16:8 or 5:2. Few controlled trials have studied OMAD specifically in healthy adult populations over meaningful durations. The available data raise legitimate concerns about lean mass preservation with very prolonged fasting periods, as protein synthesis appears to be more efficiently stimulated by multiple protein-containing meals distributed across the day than by a single large intake — particularly relevant for older adults and those seeking to maintain or build muscle mass. The practicality issues are also significant: OMAD is poorly tolerated long-term by most people who attempt it, and adherence data suggest high dropout rates in the studies that have examined it. For individuals with specific metabolic conditions under direct medical supervision, OMAD may have a clinical role. For the general population seeking metabolic benefit from intermittent fasting, the evidence does not support OMAD as preferable to better-studied and more sustainable alternatives.
Choosing a Protocol
In my reading of the comparative trial literature, 16:8 and 5:2 produce broadly similar metabolic outcomes in direct comparisons, and both are substantially better evidenced than OMAD. The decision between them is appropriately personal rather than evidence-dictated — the trials do not show a meaningful superiority of one over the other that would justify a blanket recommendation. What the Wilkinson et al. (2020) data for a 10-hour eating window suggest is that metabolic improvement is achievable without explicit caloric restriction in populations with metabolic dysfunction, which is an encouraging finding for the practical utility of TRE approaches. What the literature does not support is the idea that any specific protocol number has unique properties independent of the underlying mechanisms: reduced eating opportunity, improved metabolic circadian alignment, and in most implementations, modest caloric reduction. Start with the protocol you will actually sustain over months, monitor metabolic markers if possible, and adjust based on what you observe.
Not medical advice. Content is informational only. Consult a qualified healthcare provider before making changes to your health regimen.
Leave a Reply